Business Wire

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy

Jaa

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/

New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to ...

New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics)

According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks, and there is currently no licensed treatment proven to neutralize the virus.

During recent outbreaks of EVD in West Africa, passive immunotherapy with convalescent plasma containing polyclonal antibodies from recovered patients was used as an effective treatment. However, the amount and availability of these medicines are limited by the number of survivors.

SAB-139 was produced from SAB’s proprietary DiversitAb™ platform utilizing transgenic cattle (Tc Bovine™) to produce large amounts of natural human, rather than bovine, antibodies in response to an antigen—in this case EVD.

“This study demonstrates that a human polyclonal antibody-based product can be used to prevent EVD in the most advanced animal model available. This is impressive when one considers that SAB-139 did not require the use of plasma or cells from human EVD survivors,” said Jay Hooper, M.D., chief of the molecular virology branch of USAMRIID. “The ability to rapidly produce a human polyclonal antibody product without the need for material from infected animals or humans could be particularly useful when combating novel emerging infectious diseases.”

In the study, all animals treated with SAB-139 at one-day or three-days post-infection survived versus none of the control animals. In addition, the animals treated with SAB-139 exhibited no symptoms of EVD.

“Polyclonal antibodies are a powerful tool against emerging infectious diseases,” said Eddie J. Sullivan, PhD, SAB Biotherapeutics president and CEO. “They are our body’s natural defense to combat pathogens. With our platform, we can rapidly produce large amounts of targeted human antibodies without using humans—the limiting factor in current convalescent therapies in responding to a widespread outbreak.”

To produce the immunotherapy, Tc Bovine were vaccinated with the EVD antigen. Within a brief period of time, they produced significant amounts of fully human antibodies to combat the virus. Plasma was then collected, in the same way it is collected from human donors, and purified to isolate the antibodies that become the treatment.

“Our DiversitAb platform continues to demonstrate the ability to rapidly produce targeted immunotherapies to emerging infectious diseases with epidemic potential,” added Sullivan. “We will continue to work with our collaborators to develop life-saving medicines for both patients and those who care for them to prevent or stop an outbreak.”

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB) is a clinical stage biopharmaceutical company leading the science and manufacturing of human antibody therapeutics. Utilizing some of the most advanced polyclonal antibody science, SAB is delivering the world’s first large-scale platform to create fully human immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.

Contact information

For SAB Biotherapeutics, Inc.
Melissa Ullerich, +1 605-695-8350
mullerich@sabbiotherapeutics.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies15.11.2018 14:30Tiedote

Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer. Specifically, these targets are enzymes within the helicase and histone acetyltransferase (HAT) families that when dysregulated have been linked to the development of cancers that currently lack therapeutic options. “Boehringer Ingelheim’s collaboration with Epizyme furthers our strategic vision to profoundly impact the oncology treatment landscape by enabling a new generation of precision medicines,” said Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research, Boehringer Ingelheim. “We are excited to launch this partnership with Epizyme and to work together with them to advance epigenetic inhibitors that have the potential to transform the lives of patients and help win t

New Direct-to-home Satellite TV Bouquet for the Former Yugoslavian Countries from Telekom Srbija and SES15.11.2018 13:34Tiedote

Viewers in Serbia, Bosnia and Herzegovina, and Montenegro will soon have access to new content delivered by Telekom Srbija from SES’ key orbital location at 23.5 degrees East. SES announced today that the main telecommunication operator in Serbia has signed a multi-year and multi-transponder contract for service on its Astra satellite to launch Telekom Srbija’s new Direct-to-Home (DTH) platform which will start broadcasting in all three countries simultaneously mid-December. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005405/en/ New Direct-to-home Satellite TV Bouquet for the Former Yugoslavian Countries from Telekom Srbija and SES (Photo: Business Wire) The new DTH platform will enable Telekom Srbija to broadcast more than 150 channels, including up to 30 in High Definition (HD). All Serbian public television channels will also be available on the platform, bringing a complete selection of content to viewers in the

Great Eastern Energy Corporation to Venture into Shale Gas Exploration15.11.2018 13:18Tiedote

Great Eastern Energy Corporation Limited (LSE: GEEC), the fully integrated, leading Indian Coal Bed Methane (“CBM”) Company, today announced an upgrade in its resources at its Raniganj (South) block, which has been provided by the independent reserve engineers, Advance Resources International, Inc. (“ARI”). The Government of India has permitted exploration and exploitation of all types of hydrocarbons including shale resources under the existing CBM Contracts. ARI has made the following assessment of the CBM and Shale resources in the Raniganj (South) block: Classification Category SHALE Resources (TCF) CBM Resources (TCF) Total Resources (TCF) Original-Gas-In-Place (“OGIP”) Low Estimate 1.40 2.62 4.02 Best Estimate 3.51 6.13 High Estimate 6.63 9.25 Classification Resource Type Category Gross Recoverable Gas (BCF) Total Future Net Revenues ($ Million) Undiscounted Discounted at 10% per annum Reserves CBM 1P 336.00 $2,037.00 $675.50 2P 510.80 $3,073.00 $965.90 3P 594.70 $3,535.10 $1,076

MultiBank Group Expands Across Europe Making It One of the Largest Financial Derivatives Companies Worldwide15.11.2018 12:46Tiedote

In December 2017, MultiBank Group announced the launch of its Asset Management business and the establishment of its European headquarter in Frankfurt, Germany. Since then, the Group’s asset management business has taken off, while the performance of the MultiBank Index linked Note, listed on the Frankfurt Stock Exchange, has reached an all time high at EUR 1,357 today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005376/en/ MultiBank Group Global Presence. (Photo: Business Wire) As such, with the expansion in Europe, the Group has now offices in Hong Kong, Frankfurt, Sydney, Vienna, Barcelona, Beijing, Guangzhou, Ho Chi Minh City, Los Angeles, Cyprus, the British Virgin Islands and the Cayman Islands, with further prompt expansion anticipated in Dubai, London, Santiago (Chile) and Jakarta (Indonesia). This will make MultiBank Group one of the largest online financial derivatives providers with over 310,000 clients a

GSMA Welcomes Germany’s 5G Spectrum Award, but Cautions against Unnecessary Conditions15.11.2018 11:00Tiedote

The GSMA today welcomed the German government’s decision to release the entire 3.4 to 3.8 GHz band (C-Band), essential for the future development of 5G services globally. Making available all of the spectrum in this critical band for 5G, in a timely manner, shows Germany’s commitment to European and global 5G leadership. However, the GSMA warns that some of the currently proposed conditions on the allocation of these vital frequencies may slow Germany’s 5G future. Ultra-fast 5G networks will form the foundation of the world’s digital economy, supporting a wide variety of industry sectors. Imposing unnecessary conditions that limit mobile operators’ ability and potential to deliver 5G creates a risk for all, industries and citizens alike. “The C-Band is the most vital frequency band for 5G. Germany is demonstrating 5G leadership in the timely release of this vital spectrum, but risks undercutting its 5G future with unnecessary obligations,” said Mats Granryd, Director General, GSMA. “Sp

Entersekt Sets Sights on the Nordics15.11.2018 11:00Tiedote

Entersekt, an innovator in mobile-first fintech solutions, today announced its entry into the competitive Nordic market. The identity and payments enablement provider serves banks and other enterprises operating in 45 countries. Entersekt’s interest in Scandinavia derives from its openness to digital banking and payments innovation. Digitization may be transforming business in every corner of the world, but few regions have experienced the wholesale change in consumer payments behaviour that the Nordics have. While governments, central banks, and the banking industry as a whole have pushed a cashless agenda for several years now, many point to Nordic consumers’ enthusiastic adoption of cashless transacting as the true driver behind the boom in digital payments. Consumers in the region have never been hidebound to payments innovation, as smart card penetration rates demonstrated years ago. Payments-ready smartphones are, of course, everywhere and the retail NFC infrastructure is superb.

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme